Gillian A. Carleton

This study identifies PRDX1 as a negative regulator of T cell effector function in the ovarian tumor microenvironment, showing its impact on cytokine production, metabolism, and viability.

This study shows that disrupting autophagy in CAR-T cells enhances their metabolic activity and improves their ability to reject ovarian tumors in vivo.

This study shows that methionine restriction affects CD8+ T cell function through polyamine synthesis, but does not improve antitumor efficacy in vivo.

This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.